Lupin Share Price in Focus; Receives Tentative USFDA Approval for Apixaban Oral Suspension

Lupin has received tentative approval in the U.S. for its Apixaban Oral Suspension 1.25 mg/mL. The product is a liquid version of apixaban; the active ingredient used in Eliquis. 

The formulation is meant for adults who need anticoagulation therapy. It also gives patients who have trouble swallowing tablets an alternative way to take the medicine. 

Liquid Form of Apixaban 

Lupin's product contains apixaban in a 1.25 mg/mL oral suspension. Instead of taking the medicine as a tablet, patients would be able to take it in liquid form. 

The company said the formulation is intended to provide another administration option for adults requiring anticoagulation treatment. 

Focus on Easier Administration 

The new formulation could be useful for patients who find tablets difficult to swallow. This is the main difference highlighted by Lupin between the suspension and the more familiar tablet form. 

The product uses the same active ingredient, while changing how the medicine is administered. 

Lupin CEO on New Formulation 

Vinita Gupta, CEO of Lupin, said the tentative approval reflects the company's focus on medicines that address patient needs. 

She added that the oral suspension expands the ways in which apixaban could be administered and forms part of Lupin's differentiated medicine portfolio. 

Production Planned at New Jersey Facility 

Lupin said the product will be manufactured at its Somerset, New Jersey facility after final approval. The company plans to use its U.S.-based manufacturing operations for production and supply. 

The facility is expected to support the product's manufacturing and supply requirements in the U.S. market. 

Read More: Aegis Logistics Share Price in Focus as Board Approves Fund Raise of Up To ₹6,000 Crore! 

Lupin Share Price Performance  

As of 28 September 2026, at 2:52 PM, Lupin Ltd share price is trading at ₹2,060 per share, reflecting a decline of 1.49% from the previous trading session. 

Conclusion 

Lupin's apixaban oral suspension adds a liquid administration option for adults requiring anticoagulation therapy, particularly those who may have difficulty swallowing tablets. The company has also identified its New Jersey facility for manufacturing once the product receives final approval. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.